Dunhill Financial’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$43.7K Sell
109
-704
-87% -$78.5K 0.01% 369
2026
Q2
$89K Buy
813
+2
+0.2% +$207 0.02% 235
2026
Q1
$84.3K Sell
811
-3,215
-80% -$342K 0.02% 237
2025
Q4
$415K Buy
4,026
+2,040
+103% +$198K 0.1% 76
2025
Q3
$179K Sell
1,986
-847
-30% -$74.2K 0.05% 142
2025
Q2
$249K Buy
+2,833
New +$246K 0.07% 98

Other funds holding PPH

Dunhill Financial's PPH Position: Q3 2026 in Review

Dunhill Financial reduced its VanEck Pharmaceutical ETF (PPH) stake by 87% in Q3 2026, selling an estimated $78.5K and leaving 109 shares worth $43.7K. The position accounts for 0.01% of the portfolio, ranked #369.

Dunhill Financial first reported a position in PPH in Q2 2025 and has held it in 6 quarters since. The position peaked at $415K in Q4 2025. 156 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • Dunhill Financial held 109 shares of VanEck Pharmaceutical ETF worth $43.7K as of Q3 2026.
  • Dunhill Financial sold 704 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $78.5K.
  • VanEck Pharmaceutical ETF made up 0.01% of Dunhill Financial's portfolio in Q3 2026, its #369 holding.
  • Dunhill Financial first reported a position in VanEck Pharmaceutical ETF in Q2 2025 and has held it in 6 quarters since.
  • Dunhill Financial's VanEck Pharmaceutical ETF position peaked at $415K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on Dunhill Financial's 13F filing for Q3 2026, filed 16 Nov 2026.